ORAL USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS Foss et al.
Serial No.: Not yet assigned Docket No.: P0453.70113US04

Chronic Methadone Users Responding to Advertisement N = 242 Not Qualified for Screening (N = 182) \geq 3 Bowel Movements/wk (n = 81) Lactose Intolerance (n = 23)Other (n=78) Qualified for Screening (N = 60) Not Consented (N = 38) No Show for Screening (n = 31)Illicit Drug Use (n = 2) Others (n = 5)Consented (N = 22)Randomization (N = 22)Assigned to Receive Placebo (n = 11) Assigned to Receive Intravenous Methylnaltrexone (n = 11) Followed Up for 1st Day Trial (n = 11) Followed Up for 1st Day Trial (n = 11) Followed Up for 2nd Day Trial (n = 11) Followed Up for 2nd Day Trial (n = 11) Completed Trial (n = 11)Completed Trial (n = 11)

FIG. 1

ORAL USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS Foss et al.

Serial No.: Not yet assigned Docket No.: P0453.70113US04




FIG. 2

ORAL USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS Foss et al.

Serial No.: Not yet assigned Docket No.: P0453.70113US04





FIG. 3

ORAL USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS

Foss et al. Serial No.: Not yet assigned Docket No.: P0453.70113US04



ORAL USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS Foss et al.
Serial No.: Not yet assigned Docket No.: P0453.70113US04

